Uncategorized
Glaukos Corporation Announces Second Quarter 2020 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2020. Key highlights include: Q2 2020 net sales of $31.6 million, compared to $58.6 million in Q2 2019. Glaucoma Q2 2020 net sales of $24.9 million, compared to $58.6 million in Q2 2019. Corneal H